Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Erwinia Asparaginase, Venetoclax, and Blinatumomab in R/R B-ALL
NCT07133997Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Asparaginase erwinia chrysanthemi and venetoclax in B cell acute lymphoblastic leukemia (B-ALL), sponsored by City of Hope. Primary endpoints: Incidence of adverse events, Dose-limiting toxicities and 3 more. Started May 2026; status: recruiting.
02
Drugs
Asparaginase erwinia chrysanthemivenetoclax
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07133997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133997.